Mantle Cell Lymphoma

Andre H. Goy, MD, discusses the potential utility of lisocabtagene maraleucel in mantle cell lymphoma.

Tazemetostat as a single agent or in combination with zanubrutinib demonstrated antitumor activity in mantle cell lymphoma cell lines with intrinsic resistance to BTK inhibitors, suggesting that the agent could be a promising therapeutic option for patients with primary relapsed/refractory disease.

Brian Till, MD, discusses the safety and efficacy of lisocabtagene maraleucel compared with other products under exploration in patients with mantle cell lymphoma.

Preetesh Jain, MD, PhD, discusses ongoing research efforts in mantle cell lymphoma.

Andre Goy, MD, discusses the clinical implications of CAR T-cell therapy in mantle cell lymphoma.

Brian Till, MD, discusses the utility of brexucabtagene autoleucel in mantle cell lymphoma.

Peter Martin, MD, discusses selecting treatment for patients with high-risk mantle cell lymphoma.

Peter Martin, MD, discusses selecting among BTK inhibitors for the treatment of patients with mantle cell lymphoma.

M Lia Palomba, MD, discusses the data from the TRANSCEND-NHL-001 trial and projected how lisocabtagene maraleucel could fit into the treatment paradigm for patients with MCL.

Peter Martin, MD, discusses treatment considerations for patients with mantle cell lymphoma.

Brian Till, MD, discusses the potential durability of brexucabtagene autoleucel in mantle cell lymphoma.

Brexucabtagene autoleucel displayed significant and durable responses and a reduction in adverse effects in patients with relapsed/refractory mantle cell lymphoma.

Andre Goy, MD, discusses the next steps with CAR T-cell therapy in mantle cell lymphoma.

Peter Martin, MD, discusses the importance of developing novel therapies in mantle cell lymphoma.

Andre Goy, MD, discusses the efficacy of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma, as demonstrated in the phase 2 ZUMA-2 trial.

Sattva Neelapu, MD, discusses CAR T-cell products that have been approved by the FDA for different subtypes of lymphoma.

Peter Martin, MD, discusses the potential role of LOXO-305 in mantle cell lymphoma.

Brian Till, MD, discusses the potential to utilize CAR T-cell therapy earlier in the treatment of patients with mantle cell lymphoma.

Peter Martin, MD, discusses potential combination regimens with BTK inhibitors in mantle cell lymphoma.

As more options emerge in the mantle cell lymphoma paradigm, choosing among the agents available has become all the more challenging.

Peter Martin, MD, discusses potential drug-drug interactions with BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Hun Ju Lee, MD, discusses a phase 1/2 study evaluating cirmtuzumab in combination with ibrutinib in patients with mantle cell lymphoma or chronic lymphocytic leukemia.